2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethylene oxide | 87032-74-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethylene oxide
• 英文别名: 2,2-dimethyl-4-(2-oxiranyl)-1,3-dioxolane；2,2-dimethyl-4-oxiranyl-[1,3]dioxolane；(S)-2,2-Dimethyl-4((R)-oxiran-2-yl)-1,3-dioxolane；2-(2,2-dimethyl-1,3-dioxolan-4-yl)-ethylene oxide；2-(2,2-dimethyl-1,3-dioxolan-4-yl)-ethyleneoxide；2,2-Dimethyl-4-(oxiran-2-YL)-1,3-dioxolane
• CAS: 87032-74-4
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: VFFXYLYACPOCSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  88 °C(Press: 30 Torr)
• 密度：
  1.133±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  31
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethylene oxide 以 ammonium hydroxide 为溶剂， 生成 2-氨基-1-(2,2-二甲基-1,3-二氧戊环-4-基)乙醇
  参考文献：
  名称：

  US4570007

  摘要：

  公开号：
• 作为产物：
  描述：

  2-Chloro-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol 生成 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethylene oxide
  参考文献：
  名称：

  PFEIFFER, H.;MUETZEL, W.;SPECK, U.

  摘要：

  DOI：

文献信息

• [EN] N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR<br/>[FR] N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO) PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-1-SULFONAMIDE UTILISÉ EN TANT QUE MODULATEUR DU RÉCEPTEUR DE CHIMIOKINE
  申请人：ASTRAZENECA AB

  公开号：WO2013008002A1

  公开（公告）日：2013-01-17

  There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

  提供了一种化合物，该化合物是（a）式（I）的嘧啶磺胺或（b）其药用可接受盐，该化合物的晶型，获得该化合物的过程，用于制造该化合物的药用中间体，以及含有该化合物的药物组合物。该化合物在治疗需要调节趋化因子受体活性有益的疾病/症状中有用。
• Highly nucleophilic tributyltin azide in oxirane ring cleavage leading to 1,2-azido alcohol
  作者：Seiki Saito、Shuhei Yamashita、Toshiya Nishikawa、Yoshie Yokoyama、Masami Inaba、Toshio Moriwake

  DOI：10.1016/s0040-4039(00)99346-8

  日期：1989.1

  Enhanced reactivity of tributyltin azide has been demonstrated in nucleophilic ring cleavage of oxiranes without solvent and promoter to give 1,2-azido alcohols in good to excellent yields.

  在没有溶剂和促进剂的环氧乙烷的亲核环裂解中，已证明叠氮化三丁基锡的反应性增强，从而以良好或优异的收率得到1,2-叠氮基醇。
• [EN] PROCESS FOR THE PREPARATION OF 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND ITS COMPLEXES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACIDE 2,2',2''-(10-((2R,3S)-1,3,4-TRIHYDROXY BUTAN-2-YL)-1,4,7,10-TÉTRAAZACYCLODODÉCANE-1,4,7-TRIYL) TRIACÉTIQUE ET DE SES COMPLEXES
  申请人：BIOPHORE INDIA PHARMACEUTICALS PVT LTD

  公开号：WO2020012372A1

  公开（公告）日：2020-01-16

  The present invention relates to an improved process for the preparation of 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid, gadolinium (III) with iron metal content less than 5 ppm and free gadolinium content less than 10 ppm, which is represented by the formula (1). The present invention further relates to an improved process for the preparation of calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclo decane-1,4,7-triacetic acid known as Calcobutrol (1a) and its sodium salt of formula (1b) with purity greater than 98.0 %.

  本发明涉及一种改进的制备过程，用于制备2,2',2''-(10-((2R,3S)-1,3,4-三羟基丁醇-2-基)-1,4,7,10-四氮杂十二环-1,4,7-三基) 三乙酸，其中钆（III）的铁含量小于5 ppm，自由钆含量小于10 ppm，该化合物由式（1）表示。本发明还涉及一种改进的制备过程，用于制备10-(2,3-二羟基-1-(羟甲基)丙基)-1,4,7,10-四氮杂环己烷-1,4,7-三乙酸的钙络合物，也称为Calcobutrol（1a），以及其纯度大于98.0%的钠盐，其化学式为（1b）。
• CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE
  申请人：Gullberg Britt Anne Ingela

  公开号：US20120015927A1

  公开（公告）日：2012-01-19

  There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

  提供了N-[2-[[(2,3-二氟苯基)甲基]硫]-6-[(1R,2S)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]1-氮杂环磺酰胺无水晶形态。这种化合物/形态可能在调节趋化因子受体活性有益的疾病/病症治疗中有用。
• 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
  申请人：——

  公开号：US20020176823A1

  公开（公告）日：2002-11-28

  1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I A 1 in which R 1 means hydrogen or a metal ion equivalent independent of one another and R 2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.

  通式为IA1的1,4,7,10-四氮杂环十二烷丁基三醇化合物，其中R1表示氢或金属离子当量，独立于彼此，R2表示丁基三醇基团，以及它们与有机或无机碱或氨基酸的盐是有价值的药物制剂。